Evidence map›Paper›PMID 26471496›Full record

ArticleBMC cancer2015

Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival.

Aminah Jatoi, Nathan R Foster, Kimberly R Kalli, Robert A Vierkant, Zhiying Zhang, Melissa C Larson, Brooke Fridley, Ellen L Goode

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aminah JatoiDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. jatoi.aminah@mayo.edu.
Nathan R FosterDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Kimberly R KalliDepartment of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Robert A VierkantDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Zhiying ZhangDepartment of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Champaign, IL, USA.
Melissa C LarsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Brooke FridleyDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
Ellen L GoodeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
NCI NIH HHS P30 CA015083NCI NIH HHS P30CA15083NCI NIH HHS P50 CA136393NCI NIH HHS P50CA136393NCI NIH HHS R01 CA122443NCI NIH HHS R01CA122443
6 · The paper itself

Abstract

backgroundPrior studies have described a reduced risk of developing ovarian cancer with the use of oral contraceptives. In this context, we decided to examine if oral contraceptive use prior to a diagnosis of ovarian cancer is associated with better overall and progression-free survival.

methodsThis retrospective cohort study included ovarian cancer patients who were seen at the Mayo Clinic in Rochester, Minnesota from 2000 through 2013. Patients completed a risk factor questionnaire about previous oral contraceptive use, and clinical data were extracted from the electronic medical record.

resultsA total of 1398 ovarian cancer patients responded to questions on oral contraceptive use; 571 reported no prior use with all others having responded affirmatively to oral contraceptive use. Univariate analyses found that oral contraceptive use (for example, ever versus never) was associated with better overall survival (hazard ratio (HR) 0.73 (95 % confidence interval (CI): 0.62, 0.86); p = 0.0002) and better progression-free survival (HR 0.71 (95 % CI: 0.61, 0.83); p < 0.0001). In multivariate analyses, contraceptive use continued to yield a favorable, statistically significant association with progression-free survival, but such was not the case with overall survival.

conclusionsThis study suggests that previous oral contraceptive use is associated with improved progression-free survival in patients diagnosed with ovarian cancer.

Indexed as

Disease-Free SurvivalAdultAgedAged, 80 and overCohort StudiesContraceptives, Oral, HormonalFemaleHumansMiddle AgedMultivariate AnalysisNeoplasm StagingOvarian NeoplasmsRetrospective StudiesRisk FactorsContraceptives, Oral, Hormonal

Identifiers

PMID26471496
PMCPMC4608126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.